RxDoctor Payments Data

Kara Stackley, NP

Nurse Practitioner · Saint Louis, MONPI 1306146295

Payments from drug & device makers

$383in general payments, 2019–2025

Across 16 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$125
  • AbbVie$92
  • Boehringer Ingelheim$38
  • GSK$36
  • Exact Sciences$21
  • Pfizer$20
  • plus $53 from 4 others

What the payments were for

  • Food & beverage$37096%
  • Entertainment$144%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$383 in reported general payments places this provider in the 65th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$31,929
Medicare patients
165
Services billed
581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$32,258
EliquisApixaban24$27,812
JardianceEmpagliflozin17$18,405
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$17,134
ArexvyRsvpref3 Antigen/As01e/Pf29$8,261
Semglee (Yfgn) PenInsulin Glargine-Yfgn11$4,318
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$2,883
Atorvastatin Calcium167$1,436
Candesartan Cilexetil14$1,188
Gabapentin65$1,126
Albuterol Sulfate HfaAlbuterol Sulfate43$980
Levothyroxine Sodium94$962
Wixela InhubFluticasone Propion/Salmeterol11$868
Duloxetine Hcl23$826
Amlodipine Besylate136$784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$11$32,25824 claims
PfizerEliquis$20$27,81224 claims
GSKTrelegy Ellipta, Arexvy$36$25,39447 claims
Boehringer IngelheimJardiance$38$18,40517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →